Immobilized GUCY2C Fc Chimera Protein, Human (Cat. No. UA010217) at 2.0μg/ml (100μl/well) can bind Biotinylated Anti-human GUCY2C Monoclonal Antibody (Indusatumab) (Cat. No. UA016061) with EC50 of 5.10-7.02 ng/ml.
Anti-human GUCY2C Monoclonal Antibody (Indusatumab)
Anti-human GUCY2C Monoclonal Antibody (Indusatumab)
Price:
Regular price
$285 USD
Regular price
Sale price
$285 USD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Host | Human |
| Antigen | GUCY2C |
| Antibody Type | Human mAb |
| Purification | Protein A |
| Concentration | 2 mg/ml |
| Endotoxin | <1EU/mg |
| Physical Appearance | Liquid |
| Storage Buffer | PBS pH7.4, containing no preservative |
| Stability & Storage | 2 to 8 °C for 2 weeks under sterile conditions; |
Background
GUCY2C (guanylyl cyclase C) is a transmembrane receptor protein predominantly expressed in intestinal epithelial cells. Upon activation by endogenous ligands guanylin and uroguanylin, it catalyzes GTP to generate cGMP, thereby regulating intestinal fluid secretion, ion transport, and mucosal barrier homeostasis. In colorectal cancer, GUCY2C exhibits tumor-specific overexpression in over 95% of cases while remaining virtually absent in extra-intestinal tissues, making it an ideal tumor-specific target. Clinically, GUCY2C serves not only as a diagnostic and prognostic biomarker for colorectal cancer but also as a core target for targeted therapeutics—from the first-generation antibody-drug conjugate Indusatumab (TAK-264) to second-generation ADCs (TAK-164), as well as bispecific antibodies and CAR-T cell therapies. GUCY2C-targeted treatments are currently undergoing a critical transition from proof-of-concept to clinical translation, offering novel directions for precision therapy in metastatic colorectal cancer and other gastrointestinal malignancies.
Picture
Picture
ELISA
